- Home
- AMED vs DYN Comparison
AMED vs DYN Comparison
Compare AMED & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMED
- DYN
- Stock Information
- Founded
- AMED 1982
- DYN 1984
- Country
- AMED United States
- DYN United States
- Employees
- AMED N/A
- DYN N/A
- Industry
- AMED Medical/Nursing Services
- DYN Medicinal Chemicals and Botanical Products
- Sector
- AMED Health Care
- DYN Health Care
- Exchange
- AMED Nasdaq
- DYN Nasdaq
- Market Cap
- AMED 3.0B
- DYN 2.6B
- IPO Year
- AMED N/A
- DYN 2020
- Fundamental
- Price
- AMED $92.17
- DYN $8.28
- Analyst Decision
- AMED Hold
- DYN Strong Buy
- Analyst Count
- AMED 5
- DYN 12
- Target Price
- AMED $101.00
- DYN $47.73
- AVG Volume (30 Days)
- AMED 320.3K
- DYN 2.2M
- Earning Date
- AMED 04-23-2025
- DYN 05-01-2025
- Dividend Yield
- AMED N/A
- DYN N/A
- EPS Growth
- AMED N/A
- DYN N/A
- EPS
- AMED 1.31
- DYN N/A
- Revenue
- AMED $2,348,324,000.00
- DYN N/A
- Revenue This Year
- AMED $6.54
- DYN N/A
- Revenue Next Year
- AMED $5.32
- DYN N/A
- P/E Ratio
- AMED $70.98
- DYN N/A
- Revenue Growth
- AMED 5.00
- DYN N/A
- 52 Week Low
- AMED $82.15
- DYN $8.94
- 52 Week High
- AMED $98.95
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- AMED 48.96
- DYN 29.09
- Support Level
- AMED $91.48
- DYN $8.94
- Resistance Level
- AMED $93.25
- DYN $12.00
- Average True Range (ATR)
- AMED 0.74
- DYN 0.80
- MACD
- AMED -0.02
- DYN -0.19
- Stochastic Oscillator
- AMED 56.15
- DYN 0.77
About AMED Amedisys Inc
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.